MedicaidPrior AuthMedium impact
Drug Use Review (DUR) Board approves changes effective March 3, 2025
Nevada Medicaid·NV · Pulmonology, Allergy & Immunology, Rheumatology·Pharmacy
Effective date
Mar 3, 2025
We identified it
Jun 21, 2026
Summary
Nevada Medicaid has added new prior authorization requirements for four respiratory and allergy biologic medications: Fasenra for EGPA treatment, Dupixent for COPD, Tezspire, and Adbry. These changes require prior authorization forms to be submitted through the pharmacy point-of-sale system.
Action Required
By March 3, 2025: Providers prescribing Fasenra for EGPA, Dupixent for COPD, Tezspire, or Adbry must complete prior authorization forms available at https://nv.primetherapeutics.com/provider/forms before prescribing. Update EMR templates to include prior auth reminders for these medications. Failure to obtain prior authorization will result in prescription rejections at pharmacy point-of-sale.